ArticleJournal of neuropathology and experimental neurology2025
Clinicopathological characterization of enteric glia in colorectal cancer: Insights from a population-based cohort.
Article in Journal of neuropathology and experimental neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neural cues differentially modulate colorectal cancer cell behavior depending on patients' genomic background.iScience · 2026Article
- Enteric neuro-immune-tumor ecosystem in pancreatic, colorectal, and gastric malignancies: context dependence and translational priorities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Enteric glia contribute to the regulation of mucosal homeostasis and intestinal immunity. Enteric glia dysfunction is linked to various gastrointestinal disorders. We aimed to characterize the phenotype of enteric glia in colorectal cancer (CRC) and examine their association with CRC patient characteristics. Healthy, adenoma, and tumor tissues from CRC patients were immunohistochemically stained for the glial markers S100B and glial fibrillary acidic protein (GFAP). GFAP-positive enteric glia were identified within carcinoma tissue stroma but were absent in normal mucosa or adenoma tissue from the same patients. S100B staining was detected in all sample types. Two CRC patient cohorts (n = 447 and n = 324) were analyzed for GFAP staining and to assess association of GFAP immunoreactivity with patient characteristics. This indicated that GFAP-positive cells might be associated with tumor localization and median survival. High-density GFAP staining was associated with improved survival in the study cohort (HR = 0.56; P = 0.030), but not the validation cohort (HR = 0.85; P = 0.606). These findings suggest that CRC induces GFAP expression in enteric glia. While prognostic value of GFAP could not be confirmed, future studies are needed to elucidate the role of enteric glia in CRC prognosis and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.